Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.

N/AEnrolling By InvitationNCT07154238

Novo Nordisk A/S2,546 enrolled

Overview

The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.

Study Type

OBSERVATIONAL

Enrollment

2,546

Conditions

Obesity

Interventions

No treatment givenOTHER

No treatment given

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes". 1. Electronically provided consent obtained before any study-related activities can be completed. 2. Age above or equal to 18 years at the time of providing informed consent. 3. Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain. 4. Have been prescribed and initiated injectable semaglutide for weight management prior to study screening. * For an eligible participant (HCPs), all inclusion criteria must be answered "yes". 1. Electronically provided consent obtained before any study-related activities can be completed. 2. Practice in a participating country: Australia, Germany, UAE, and Spain. 3. See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month. 4. Treat at least 10 adult patients per month for weight management. 5. Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs). 6. Prescribe injectable semaglutide for weight management. 7. Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others. Exclusion Criteria: * For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no". 1. Unwillingness or language barriers precluding adequate understanding or cooperation. 2. Is currently or planning to become pregnant in next six months. 3. Is taking injectable semaglutide for Type 2 diabetes management only. * For an eligible participant (HCPs), all exclusion criteria must be answered "no". 1. Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview. 2. Unwillingness or language barriers precluding adequate understanding or cooperation. 3. Only treats patients under 18 years of age.

Locations (1)

Novo Nordisk Investigational Site

Bad Oeynhausen, Germany

Outcomes

Primary Outcomes

Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management

Patient Quantitative Segment Multi select from a defined list Single select from a defined list Numeric entry Open-ended type-in Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Description of the experience of individuals initiated on injectable semaglutide for weight management through personal perception of physical and mental health and self-reported QoL

Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates extremely dissatisfied and 7 indicates extremely satisfied) Single select from a defined list EQ-5D-5L Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Individual-reported change in BMI since initiation

Patient Quantitative Segment Numeric entry (BMI calculated based on self-reported height and weight)

Time frame: At the time of survey response (Day 1)

Individual-reported achievement of weight loss goal

Patient Quantitative Segment Yes/No; percentage of weight loss goal achieved Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Individual-reported change in weight since initiation

Patient Quantitative Segment Numeric entry in (kgs); percentage of weight change Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Individual-reported changes in daily life since initiation on injectable semaglutide

Patient Qualitative Segment Open-ended commentary

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Treatment expectation of individuals initiated on injectable semaglutide of ability to achieve weight loss goal using injectable semaglutide

Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates not at all confident and 7 indicates extremely confident) Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Expectation for length of time of treatment to desired result from date of initiation on injectable semaglutide at baseline

Patient Quantitative Segment Numeric entry months Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Expectation of individuals initiated on injectable semaglutide for weight management who believe they will have greater success in achieving their weight loss with the use of injectable semaglutide

Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Expected benefits of injectable semaglutide

Patient Quantitative Segment Multi select from a defined list

Time frame: At the time of survey response (Day 1)

Satisfaction with weight loss since initiation

Patient Quantitative Segment 7-point Likert scale for satisfaction (where 1 indicates extremely dissatisfied all and 7 indicates extremely satisfied) Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Overall satisfaction with injectable semaglutide

Patient Quantitative Segment 7-point Likert scale for satisfaction (where 1 indicates extremely dissatisfied all and 7 indicates extremely satisfied) Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Individual-reported changes in perception of injectable semaglutide since initiation

Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Attitudes of individuals related to obesity or weight related stigmatization or discrimination prior to/since/due to initiation on injectable semaglutide

Patient Quantitative Segment Multi select from a defined list

Time frame: At the time of survey response (Day 1)

Attitudes of individuals initiated on injectable semaglutide for weight management related to obesity as a chronic disease

Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree)

Time frame: At the time of survey response (Day 1)

Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being their responsibility

Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree)

Time frame: At the time of survey response (Day 1)

Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being more likely with use of prescription medication for weight loss (AOMs)

Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree)

Time frame: At the time of survey response (Day 1)

Degree of knowledge of individuals initiated on injectable semaglutide for weight management related to how prescription weight loss medications (AOMs) work in the body

Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Behaviours of individuals initiated on injectable semaglutide for weight management related to making lifestyle changes in addition to initiating on injectable semaglutide for weight loss or weight management to achieve their weight loss goals

Patient Quantitative Segment Multi select from a defined list Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Attitudes of individuals initiated injectable semaglutide for weight management related to the necessity to make lifestyle changes in addition to initiating injectable semaglutide for weight loss or weight management to achieve their weight loss goals

Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Attitudes of individuals who initiated on injectable semaglutide for weight management relating to ease of maintaining lifestyle changes (e.g., eating a healthy diet and getting regular exercise) since initiating on injectable semaglutide

Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree)

Time frame: At the time of survey response (Day 1)

Individual-reported change in overall knowledge of how AOMs work from initiation on injectable semaglutide to present day

Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree)

Time frame: At the time of survey response (Day 1)

Attitudes related to viewing obesity as a chronic disease

HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary

Time frame: At the time of survey response (Day 1)

Attitudes related to belief weight loss is solely an individual's responsibility

HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary

Time frame: At the time of survey response (Day 1)

Attitudes related to belief weight loss requires use of prescription medication for weight loss (AOMs)

HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary

Time frame: At the time of survey response (Day 1)

Attitudes related to belief individuals must make lifestyle changes in addition to initiating on injectable semaglutide for weight loss or weight management to achieve their weight loss goals

HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary

Time frame: At the time of survey response (Day 1)

Attitudes related to belief individuals will have greater success in achieving their weight loss goals with use of injectable semaglutide

HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary

Time frame: At the time of survey response (Day 1)

Attitudes related to level of comfort prescribing AOMs and injectable semaglutide specifically for weight management

HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary

Time frame: At the time of survey response (Day 1)

Reasons for length of adherence

Patient Quantitative Segment Multi select from a defined list Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Future planned use of injectable semaglutide (among current users)

Patient Quantitative Segment Multi select from a defined list; Numeric entry months Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Reasons for discontinuation (among those who discontinued)

Patient Quantitative Segment Multi select from a defined list Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Likelihood to resume injectable semaglutide (specifically for weight management) after formal discontinuation and reasons

Patient Quantitative Segment 7-point Likert scale for likelihood (where 1 indicates not at all likely and 7 indicates extremely likely) Multi select from a defined list Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Individual-reported likelihood of continuation on injectable semaglutide until achieve goal weight and reasons

Patient Quantitative Segment 7-point Likert scale for likelihood (where 1 indicates not at all likely and 7 indicates extremely likely)

Time frame: At the time of survey response (Day 1)

Likelihood of continuation on injectable semaglutide after achieving weight loss goal and reasons

Patient Quantitative Segment 7-point Likert scale for likelihood (where 1 indicates not at all likely and 7 indicates extremely likely)

Time frame: At the time of survey response (Day 1)

Treatment pause initiated by individual and reasons

Patient Quantitative Segment Yes/No; Numeric entry; Multi select from a defined list Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Treatment pause initiated by HCP and reasons

Patient Quantitative Segment Yes/No; Numeric entry; Multi select from a defined list Patient Qualitative Segment Open-ended commentary

Time frame: At the time of survey response (Day 1)

Number of treatment pauses

Patient Quantitative Segment Numeric entry

Time frame: At the time of survey response (Day 1)

Among those with low likelihood to use injectable semaglutide after discontinuation, potential use of another AOM

Patient Quantitative Segment Yes/No/Not Sure

Time frame: At the time of survey response (Day 1)